Literature DB >> 12117845

Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey.

N Danchin1, O Grenier, J Ferrières, C Cantet, J-P Cambou.   

Abstract

BACKGROUND: There is evidence that several classes of drugs are beneficial for secondary prevention in patients with coronary artery disease.
OBJECTIVE: To compare the use of secondary preventive drugs in patients with acute coronary syndromes given conservative treatment or percutaneous coronary interventions.
DESIGN: The PREVENIR survey was designed to assess the management of patients with acute coronary syndromes admitted to hospital in France in January 1998. Drugs prescribed at hospital discharge were recorded retrospectively from the hospital records, and treatment at six months was assessed prospectively.
SETTING: University hospitals, general hospitals, and private clinics throughout the country.
RESULTS: Of 1394 patients participating in the survey, 668 underwent coronary angioplasty during the initial hospital stay and 706 had medical treatment only. At hospital discharge, aspirin, beta blockers, and statins were prescribed significantly more often in patients undergoing angioplasty. Using multivariate logistic regression, coronary angioplasty was an independent predictor of treatment with aspirin (odds ratio 3.55), statins (1.92), and beta blockers (1.41). Compared with treatment at discharge, only statin use differed at six months, with a significant increase both in patients treated medically and in those who had undergone angioplasty. Increased use of statins, aspirin, and beta blockers was significantly correlated with coronary angioplasty during the initial hospital stay.
CONCLUSIONS: In this national French survey, patients treated with percutaneous coronary interventions were more likely to receive secondary preventive drugs than patients receiving medical treatment alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117845      PMCID: PMC1767203          DOI: 10.1136/heart.88.2.159

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.

Authors: 
Journal:  Eur Heart J       Date:  1997-10       Impact factor: 29.983

3.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.

Authors: 
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

Review 4.  ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials.

Authors:  R Latini; A P Maggioni; M Flather; P Sleight; G Tognoni
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

5.  Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995.

Authors:  N L Smith; G E Reiber; B M Psaty; S R Heckbert; D S Siscovick; J L Ritchie; N R Every; T D Koepsell
Journal:  Am J Cardiol       Date:  1999-09-15       Impact factor: 2.778

6.  Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results.

Authors:  N Danchin; L Vaur; N Genès; M Renault; J Ferrières; S Etienne; J P Cambou
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

9.  Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.

Authors:  H V Barron; A D Michaels; C Maynard; N R Every
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

10.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

View more
  7 in total

1.  The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention.

Authors:  Jessica M Ma; Cynthia A Jackevicius; Uchenwa Genus; Vladimir Dzavik
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

2.  Undertreatment of coronary heart disease in patients undergoing coronary artery bypass surgery.

Authors:  N Sambu; D S Wald; M Seddon; I A Simpson
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

3.  Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England.

Authors:  P R Ward; P R Noyce; A S St Leger
Journal:  J Epidemiol Community Health       Date:  2004-02       Impact factor: 3.710

4.  Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry.

Authors:  G Hanania; J-P Cambou; P Guéret; L Vaur; D Blanchard; J-M Lablanche; Y Boutalbi; R Humbert; P Clerson; N Genès; N Danchin
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

5.  How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2007-03-27

6.  Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2005-02-08

7.  Present and future of secondary prevention after an acute coronary syndrome.

Authors:  Pierre-Frederic Keller; Sebastian Carballo; David Carballo
Journal:  EPMA J       Date:  2011-10-25       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.